MedTrace Logo

Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19

NCT04452617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-09-01

No results posted yet for this study

Summary

Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but few reports have assessed this combination therapy in critically ill COVID-19 patients.

Many raised concerns regarding the potential cardiac toxicity of this association.

The purpose of this monocenter retrospective observational study is to evaluate the safety of a short term treatment with hydroxychloroquine and azithromycin in critically ill patients admitted in ICU for severe COVID-19 with respiratory failure.

The main objective is to assess the incidence of severe cardiac arrhythmia e.g torsade de pointes and cardiac arrest or sudden death, during the treatment period.

Conditions

Sponsors & Collaborators

  • Institut Mutualiste Montsouris

    lead OTHER

Principal Investigators

  • Lyes KNANI, Doctor · Institut Mutualiste Montsouris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2020-04-08
Completion
2020-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452617 on ClinicalTrials.gov